Aveanna Healthcare vs Pediatrix Medical
AVAH and MD side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AVAH and MD compare
Aveanna Healthcare is the larger company, worth 1.2 times as much as Pediatrix Medical ($2.9B against $2.5B).
On earnings, Aveanna Healthcare is cheaper: it trades at 9.6× trailing earnings, against 17.1× for Pediatrix Medical.
Aveanna Healthcare grew revenue faster over the last twelve months (16.8% versus 1.9% for Pediatrix Medical).
Aveanna Healthcare keeps more of each dollar of sales as profit, with a net margin of 11.4% compared with 7.7% at Pediatrix Medical.
Aveanna Healthcare scores higher on the StockData Score (13 against 10 for Pediatrix Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AVAH | MD |
|---|---|---|
| Size and price | ||
| Market cap | $2.9B | $2.5B |
| Share price | $13.09 | $31.45 |
| Change, 1 year | 46.3% | 39.3% |
| Change, 5 years | 77.4% | 21.8% |
| Beta (5Y) | 1.40 | 0.68 |
| Employees | 32K | – |
| StockData Score | ||
| Total score | 13 (better) | 10 |
| Valuation score | 4 (better) | 2 |
| Growth score | 3 (better) | 1 |
| Performance score | 4 | 4 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 9.6× (better) | 17.1× |
| P/S | 1.1× (better) | 1.3× |
| P/B | 8.5× | 2.9× (better) |
| EV/EBITDA | 12.5× | 11.0× (better) |
| PEG | – | 0.49 |
| Fair value | $25.41 | $29.34 |
| Margin of safety | 48.5% (better) | −7.2% |
| Growth | ||
| Revenue growth (TTM) | 16.8% (better) | 1.9% |
| Revenue growth, 5Y average | 10.2% (better) | 2.0% |
| Net income growth (TTM) | 306% (better) | −7.5% |
| EPS growth (TTM) | 270% (better) | −3.2% |
| Profitability | ||
| Gross margin | 32.3% | – |
| Operating margin | 11.4% (better) | 10.9% |
| Net margin | 11.4% (better) | 7.7% |
| Return on equity | 177% (better) | 17.2% |
| Return on invested capital | 23.4% (better) | 15.4% |
| Financial health | ||
| Debt / equity | 3.84 | 0.68 (better) |
| Net debt / EBITDA | 3.48 | 0.64 (better) |
| Interest coverage | 2.6× | 6.4× (better) |
| Current ratio | 1.23 | 1.28 (better) |
| Altman Z-score | 1.99 | 2.47 (better) |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | 8.5% |
| Shareholder yield | 0.00% | 8.5% (better) |
| Ownership | ||
| Held by institutions | 93.0% | 107% |
| Held by insiders | 33.2% | 1.5% |
| Insider net buying, 12 months | −$782M | −$1.4M (better) |
| Short interest, % of float | 5.0% | 4.6% |
Go deeper
- AVAH stock overview
- AVAH income statement
- AVAH valuation and score
- MD stock overview
- MD income statement
- MD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.